Abbott Laboratories Corporation

Jonathan A Meulbroek

Steven N Anderson

Pradip Mukerji

Yung-Sheng Huang

Shie-Ming Hwang

Jim-Wen Liu

Keith A Garleb

Bryan W Wolf

Keith Brian Wheeler

Joseph P Schaller

Joseph E Walton

Milo Duane Hilty

Jin-Zhou Liu

Melinda Guzman-Harty

Terry Bruce Mazer

Theresa Siu-Ling Wai Lee

Patricia Joan Ewing

Sheila Martinson Campbell

Antibacterial phosphoinositides

It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of,onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula:

The present invention is directed to a rice flour extract (RFE) which can be used in the prophylaxis and treatment of bacterial infections, particularly bacterial infections caused by,and to a method of preparing and using such an antibacterial rice flour extract. The anti-,rice flour extract of the present invention can be prepared from commercial food grade rice flours or non-commercial food grade rice flours.

Bioactive rice flour extract useful for treatment of haemophilus influenzae infections

A process of treating a bacterial infection in a subject in need of such treatment including the step of administering to the subject an effective bactericidal amount of diacetyltartaric acid esters of mono- and diglycerides is provided. Pharmaceutical compositions containing diacetyltartaric acid esters of mono- and diglycerides as an active bactericidal agent are also provided.

Water-miscible esters of mono--and diglycerides having antibacterial

An oral rehydration solution contains indigestible oligosaccharides. Diarrhea related dehydration requires fluid and electrolyte replacement. The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of diarrhea related to C. difficile with rehydration therapy and antibiotics has proven effective, but many times relapse occurs. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection.

Oral rehydration solution containing indigestible oligosaccharides

The primary etiology of antibiotic-associated diarrhea (which may lead to pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs. The present invention involves a non-antibiotic approach to the treatment and/or prevention of C. difficile--associated diseases. A therapeutically effective amount of an indigestible oligosaccharide inhibits the infection of mammals by C. difficile when administered enterally.

Inhibition of C. difficile infections by indigestible oligosaccharides

Growing community of inventors

Lake Forest, IL, United States of America

Jonathan A Meulbroek